|
|
|
|
||
ASCO GI 2020Looks like we could possibly be getting some data from CM 040 in a couple of weeks. Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer Friday, January 24 12:00 PM- 1:30 PM and 4:30 PM- 5:30 PM BOARD A1 Abstract 478: Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. First Author: Thomas Yau |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
23256 | Re: ASCO GI 2020 | duckduffer | 1 | 12/11/2019 11:48:46 AM |
23323 | Re: ASCO GI 2020 | SirCharlesMartin | 3 | 12/29/2019 9:42:34 AM |